Sung Yong Park1, Gina Faraci1, Gary Murphy2, Christopher Pilcher3, Michael P Busch4,5, Ha Youn Lee1. 1. Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. 2. Public Health England, London, United Kingdom. 3. Department of Medicine, University of California, San Francisco, California, USA. 4. Research and Scientific Programs, Vitalant Research Institute, San Francisco, California, USA. 5. Deparment of Laboratory Medicine, University of California, California, San Francisco, USA.
Abstract
BACKGROUND: Precise and cost-efficient human immunodeficiency virus (HIV) incidence and drug resistance surveillances are in high demand for the advancement of the 90-90-90 "treatment for all" target. METHODS: We developed microdrop HIV sequencing for the HIV incidence and drug resistance assay (HIDA), a single-blood-draw surveillance tool for incidence and drug resistance mutation (DRM) detection. We amplified full-length HIV envelope and pol gene sequences within microdroplets, and this compartmental amplification with long-read high-throughput sequencing enabled us to recover multiple unique sequences. RESULTS: We achieved greater precision in determining the stage of infection than current incidence assays, with a 1.2% false recency rate (proportion of misclassified chronic infections) and a 262-day mean duration of recent infection (average time span of recent infection classification) from 83 recently infected and 81 chronically infected individuals. Microdrop HIV sequencing demonstrated an increased capacity to detect minority variants and linked DRMs. By screening all 93 World Health Organization surveillance DRMs, we detected 6 pretreatment drug resistance mutations with 2.6%-13.2% prevalence and cross-linked mutations. CONCLUSIONS: HIDA with microdrop HIV sequencing may promote global HIV real-time surveillance by serving as a precise and high-throughput cross-sectional survey tool that can be generalized for surveillance of other pathogens.
BACKGROUND: Precise and cost-efficient human immunodeficiency virus (HIV) incidence and drug resistance surveillances are in high demand for the advancement of the 90-90-90 "treatment for all" target. METHODS: We developed microdrop HIV sequencing for the HIV incidence and drug resistance assay (HIDA), a single-blood-draw surveillance tool for incidence and drug resistance mutation (DRM) detection. We amplified full-length HIV envelope and pol gene sequences within microdroplets, and this compartmental amplification with long-read high-throughput sequencing enabled us to recover multiple unique sequences. RESULTS: We achieved greater precision in determining the stage of infection than current incidence assays, with a 1.2% false recency rate (proportion of misclassified chronic infections) and a 262-day mean duration of recent infection (average time span of recent infection classification) from 83 recently infected and 81 chronically infected individuals. Microdrop HIV sequencing demonstrated an increased capacity to detect minority variants and linked DRMs. By screening all 93 World Health Organization surveillance DRMs, we detected 6 pretreatment drug resistance mutations with 2.6%-13.2% prevalence and cross-linked mutations. CONCLUSIONS: HIDA with microdrop HIV sequencing may promote global HIV real-time surveillance by serving as a precise and high-throughput cross-sectional survey tool that can be generalized for surveillance of other pathogens.
Authors: Sung Yong Park; Tanzy M T Love; Jeremy Nelson; Sally W Thurston; Alan S Perelson; Ha Youn Lee Journal: AIDS Date: 2011-10-23 Impact factor: 4.177
Authors: S Munir Alam; S Moses Dennison; Baptiste Aussedat; Yusuf Vohra; Peter K Park; Alberto Fernández-Tejada; Shelley Stewart; Frederick H Jaeger; Kara Anasti; Julie H Blinn; Thomas B Kepler; Mattia Bonsignori; Hua-Xin Liao; Joseph G Sodroski; Samuel J Danishefsky; Barton F Haynes Journal: Proc Natl Acad Sci U S A Date: 2013-10-21 Impact factor: 11.205
Authors: Ann M Dennis; Shuntai Zhou; Christopher J Sellers; Emily Learner; Marc Potempa; Myron S Cohen; William C Miller; Joseph J Eron; Ronald Swanstrom Journal: J Infect Dis Date: 2018-10-20 Impact factor: 5.226
Authors: Jesus F Salazar-Gonzalez; Elizabeth Bailes; Kimmy T Pham; Maria G Salazar; M Brad Guffey; Brandon F Keele; Cynthia A Derdeyn; Paul Farmer; Eric Hunter; Susan Allen; Olivier Manigart; Joseph Mulenga; Jeffrey A Anderson; Ronald Swanstrom; Barton F Haynes; Gayathri S Athreya; Bette T M Korber; Paul M Sharp; George M Shaw; Beatrice H Hahn Journal: J Virol Date: 2008-02-06 Impact factor: 5.103
Authors: Reshma Kassanjee; Christopher D Pilcher; Sheila M Keating; Shelley N Facente; Elaine McKinney; Matthew A Price; Jeffrey N Martin; Susan Little; Frederick M Hecht; Esper G Kallas; Alex Welte; Michael P Busch; Gary Murphy Journal: AIDS Date: 2014-10-23 Impact factor: 4.177
Authors: Nicholas Silver; Mary Paynter; Georgina McAllister; Maureen Atchley; Christine Sayir; John Short; Dane Winner; David J Alouani; Freddie H Sharkey; Kicki Bergefall; Kate Templeton; David Carrington; Miguel E Quiñones-Mateu Journal: AIDS Res Ther Date: 2018-11-08 Impact factor: 2.250
Authors: Samo Zakotnik; Nataša Knap; Petra Bogovič; Tomaž Mark Zorec; Mario Poljak; Franc Strle; Tatjana Avšič-Županc; Miša Korva Journal: Viruses Date: 2022-06-10 Impact factor: 5.818